Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Trump Lifts 25% Tariff on Indian Goods in Strategic U.S.–India Trade and Energy Deal 
Gold and Silver Prices Slide as Dollar Strength and Easing Tensions Weigh on Metals 
Singapore Budget 2026 Set for Fiscal Prudence as Growth Remains Resilient 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Gold Prices Slide Below $5,000 as Strong Dollar and Central Bank Outlook Weigh on Metals 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
RBI Holds Repo Rate at 5.25% as India’s Growth Outlook Strengthens After U.S. Trade Deal 
Dollar Near Two-Week High as Stock Rout, AI Concerns and Global Events Drive Market Volatility 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Trump Endorses Japan’s Sanae Takaichi Ahead of Crucial Election Amid Market and China Tensions 
Bank of Japan Signals Readiness for Near-Term Rate Hike as Inflation Nears Target 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
CHA Healthcare Co., a South Korean medical hospital operator, announced on Monday, June 28, that it has secured management rights to Fertility Specialists of Western Australia (FSWA) via an acquisition deal.
The FSWA is a major fertility center located in Western Australia and it was through City Fertility National Network, an Australian in-vitro fertilization (IVF) service group, that CHA Healthcare was able to make the deal. The CFNN is a subsidiary of the Korean healthcare company.
As per The Korea Economic Daily, the FSWA is running two fertility centers in Perth, and centers carry out more than 1,200 IVF treatments per year. This number is said to make up 30% of all the IVF treatments done in the region.
With its acquisition of the Australian fertility center, CHA Healthcare Co. is now aiming to conduct over 10,000 in-vitro fertilization treatments annually by the year 2026. The deal also marks the Korean medical operator's expansion in the Australian infertility treatment market.
The company first entered Australia in 2018 when it purchased the Queensland-based City Fertility, which has seven local fertility facilities. With the addition of FSWA in its acquisition portfolio, CHA Healthcare has now expanded the number of its fertility centers to 18 across AU and is targeting states that have a high percentage of women of childbearing age. Such locations include Sydney, Brisbane, and Melbourne.
"CHA Healthcare has built a solid foundation for international medical care in Australia," Cho Seong Soo, CHA Healthcare's chief executive officer, said in a statement. "We aim to expand the global network in Southeast Asian countries such as Vietnam and Indonesia."
Korea Joongang Daily reported that the deal is in line with CHA Healthcare's move to further boost its presence in the fertility treatment market in Australia. Meanwhile, the Korean healthcare firm was launched in 2013 as a subsidiary of CHA Biotech Co. Ltd, which is the leading stem cell therapeutics developer in the country. Aside from Australia and Korea, the company is also running 81 general acute care medical hospitals and IVF clinics in various countries including Singapore, the U.S., and Japan.
